ESMO Congress 2016: Three of the most important studies in the field of breast cancer
Abstract
The 2016 European Society for Medical Oncology (ESMO) annual congress highlighted the latest discoveries in different types of cancer research, including breast cancer. Immunotherapy and targeted therapies are the most rapidly evolving. This year’s meeting featured studies on targeted therapy (CDK4/6 inhibitor) plus endocrine therapy for advanced/metastatic breast cancer, a new approach in endocrine treatment, or possibility of using molecular/biological features in specific groups of patients to identify those for whom sentinel lymph node biopsy might be avoided. In this paper three selected studies dedicated to breast cancer patients, presented during the meeting, will be discussed.
Keywords: ESMOcongressbreast cancerCDK4/6 inhibitorendocrine therapy
References
- www. esmo.org..
- www.fda.gov..
- https://clinicaltrials.gov.
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive. Advanced Breast Cancer . 2016; 1056.
- Hortobagyi GN, Stemmer SM, Burris HA et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). European Society for Medical Oncology (ESMO) Kopenhaga, 2016.
- Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22): 6173–6182.
- Kim S, Loo A, Chopra R, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6–reactivating Rb in cancer. Mol Cancer Ther. 2013; 12(11 Suppl): Abstract PR02.
- INTERVIEW: Gabriel Hortobagyi MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, USA. http://www. audiomedica.com/oncology/cyclin-dependent-kinase-inhibitionovercomes-endocrine-resistance-in-advanced-breast-cancer/.
- Ellis MJ, Bondarenko I, Trishkina E et al. FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. European Society for Medical Oncology (ESMO) Congress; Copenhagen, Denmark; 2016. Abstract for LBA14_PR.
- Bregni G, Meneghini E, Galli G, et al. Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated. Annals of Oncology. 2016; 27(suppl_6).
- Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3): 311–322.
- Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1): 13–20.